<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Turn Therapeutics Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Turn Therapeutics Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/turn-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates-4</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates-4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026 Secured up to $25 Million in Growth Capital from</description>
</item>
<item>
<title>Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-secures-up-to-dollar25-million-in-financing-from-avenue-capital-group</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-secures-up-to-dollar25-million-in-financing-from-avenue-capital-group</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Financing Extends Runway and Supports Continued Advancement of Atopic Dermatitis (Eczema) and Onychomycosis (Nail Fungus) Programs LOS ANGELES--(BUSINESS</description>
</item>
<item>
<title>Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-dr-robert-redfield-as-senior-advisor-of-health-policy-and-regulatory-affairs</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-dr-robert-redfield-as-senior-advisor-of-health-policy-and-regulatory-affairs</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>LOS ANGELES, February 17, 2026--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company’s lead investigational therapy,</description>
</item>
<item>
<title>Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-present-upcoming-td-130000837</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-present-upcoming-td-130000837</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>LOS ANGELES, February 09, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference.</description>
</item>
<item>
<title>Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-announces-corporate-pipeline-130500720</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-announces-corporate-pipeline-130500720</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>LOS ANGELES, January 12, 2026--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco. Throughout the conference, Turn Therapeutics will participate in investor and partner meetings to</description>
</item>
<item>
<title>Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-martin-dewhurst-210500427</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-martin-dewhurst-210500427</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and ExpansionLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhur</description>
</item>
<item>
<title>Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-reports-third-quarter-130000901</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-reports-third-quarter-130000901</guid>
<pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
<description>Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease th</description>
</item>
<item>
<title>Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-ceo-bradley-burnam-210500913</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-ceo-bradley-burnam-210500913</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>Conversation Centered Around Healthcare Communications and Pandemic PreparednessLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced that Chief Executive Officer, Brad Burnam, spoke with Dr. Robert Redfield, M.D., former Director of the Centers for Disease Control and Prevention (CDC) about healthcare communication and ways to restore</description>
</item>
<item>
<title>Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-gx-03-technology-130000938</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-gx-03-technology-130000938</guid>
<pubDate>Tue, 11 Nov 2025 13:00:00 GMT</pubDate>
<description>Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar TherapeuticsLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “</description>
</item>
<item>
<title>Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-veteran-capital-220700409</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-veteran-capital-220700409</guid>
<pubDate>Tue, 04 Nov 2025 22:07:00 GMT</pubDate>
<description>LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership initiatives. “We are thrilled t</description>
</item>
<item>
<title>Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-enters-global-supply-113000331</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-enters-global-supply-113000331</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunitiesWESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global supply, development, and license agreement with</description>
</item>
<item>
<title>Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-provides-shareholder-highlighting-120000241</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-provides-shareholder-highlighting-120000241</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategyWESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlight</description>
</item>
<item>
<title>Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-launches-webinar-series-122200866</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-launches-webinar-series-122200866</guid>
<pubDate>Mon, 20 Oct 2025 12:22:00 GMT</pubDate>
<description>LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam. “It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community,” said Bradley Burnam, Founder and CEO of Turn Therapeutics. “But this company was built</description>
</item>
<item>
<title>Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-dr-kent-120000011</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-dr-kent-120000011</guid>
<pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
<description>Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease researchWESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectiou</description>
</item>
<item>
<title>Turn Therapeutics Appoints Arthur Golden to Board of Directors</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-arthur-golden-160700216</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-appoints-arthur-golden-160700216</guid>
<pubDate>Tue, 14 Oct 2025 16:07:00 GMT</pubDate>
<description>Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programsWESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with extensive experience in M&A transactions, shareholder relations, co</description>
</item>
<item>
<title>Turn Therapeutics to Commence Trading Today on Nasdaq</title>
<link>https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-commence-trading-today-120000812</link>
<guid isPermaLink="true">https://6ix.com/company/turn-therapeutics-inc-common-stock/news/turn-therapeutics-commence-trading-today-120000812</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ETWESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker symbol “TTRX.” The Company’s registration statement on Form S-1 was declar</description>
</item>
</channel>
</rss>